Home › Calculator › AQSZF Dividend Calculator 2026
AQSZF Dividend DRIP Calculator 2026
166666.67% YieldHealthcareAequus Pharmaceuticals Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When AQSZF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your AQSZF snowball 📈
$10,000 in AQSZF → $5.822340461279536e+43M in 10 years · $4,851,947,541,461,600,600,000,000,000,000,000,000,000,000,000,000.00/month
About Aequus Pharmaceuticals Inc. (AQSZF) — Dividend Analysis 2026
Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, dedicated to the development and commercialization of medicinal products across the country. The company concentrates its efforts on several key medical disciplines, including neurological conditions, ophthalmology, and transplantation medicine. Its current commercial portfolio features: Vistitan, an ophthalmic solution designed to lower elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Tacrolimus IR, an immunosuppressive drug prescribed for the management and prevention of acute organ rejection subsequent to transplantation procedures. The Evolve range of dry eye products, formulated to alleviate various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness. Additional preservative-free ophthalmic products. In its development pipeline, Aequus is advancing: Extended-release oral tablet formulations of Topiramate XR and Oxcarbazepine XR, both intended for the treatment of epilepsy. AQS1303, a transdermal patch containing pyridoxine/doxylamine, aimed at addressing nausea and vomiting during pregnancy. AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. Aequus Pharmaceuticals has forged strategic alliances with other industry players, including Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for the marketing of extended-release anti-epileptic medications; and Medicom Healthcare Ltd., with whom they collaborate on preservative-free treatments within ophthalmology. The company was established in 2013.
Compare AQSZF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full AQSZF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open AQSZF position with:
🌍 AQSZF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold AQSZF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 166666.67% | 166663.87% | $16,666,667 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 141666.67% | 141663.87% | $14,166,667 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 133333.34% | 133330.54% | $13,333,334 / yr |
| 🇬🇧 UK ISA | 0% | 166666.67% | 166663.87% | $16,666,667 / yr |
| 🇬🇧 UK Taxable | 8.75% | 152083.34% | 152080.54% | $15,208,334 / yr |
| 🇨🇦 TFSA | 0% | 166666.67% | 166663.87% | $16,666,667 / yr |
| 🇨🇦 CA Taxable | 25% | 125000.00% | 124997.20% | $12,500,000 / yr |
| 🇦🇺 Super (pension) | 15% | 141666.67% | 141663.87% | $14,166,667 / yr |
| 🇦🇺 AU Taxable | 30% | 116666.67% | 116663.87% | $11,666,667 / yr |
| 🇩🇪 DE Taxable | 26.375% | 122708.34% | 122705.54% | $12,270,834 / yr |
| 🇫🇷 FR Taxable | 30% | 116666.67% | 116663.87% | $11,666,667 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 AQSZF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 AQSZF Dividend Payment Schedule
AQSZF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 AQSZF vs Healthcare Benchmarks
How AQSZF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for AQSZF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ AQSZF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the AQSZF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Aequus Pharmaceuticals Inc. (AQSZF) is currently trading at $0.00, 99% below its 52-week high. The current dividend yield is 166666.67% based on an annual payout of $2.00 per share.
AQSZF (Aequus Pharmaceuticals Inc.) — 166666.67% Dividend Yield Analysis
Aequus Pharmaceuticals Inc. (AQSZF) is a healthcare stock currently trading at $0.00 with a dividend yield of 166666.67%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (166666.67%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.